International, Randomized, Placebo-Controlled, Double-Blind Phase III Study of Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer: MONET1

2012183 citationsJournal Articlegreen Open Access

Authors

Giorgio V. Scagliotti · Zaporizhzhya National University

Ihor Vynnychenko · Zaporizhzhya National University

Keunchil Park · Zaporizhzhya National University

Yukito Ichinose · Zaporizhzhya National University

Kaoru Kubota · Zaporizhzhya National University

Fiona Blackhall · Zaporizhzhya National University

Robert Pirker

Abstract

Motesanib plus carboplatin/paclitaxel did not significantly improve OS over carboplatin/paclitaxel alone in patients with advanced nonsquamous NSCLC or in the adenocarcinoma subset.

Topics & Keywords

Lung Cancer Treatments and Mutations Gastric Cancer Management and Outcomes Lung Cancer Research Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 30, Issue 23, pp. 2829-2836

DOI: 10.1200/jco.2011.41.4987

Field-Weighted Citation Impact: 27.64